Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 399

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 2
Chunk 399
---
 that respond to those
risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial
statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as
evaluating the overall presentation of the consolidated financial statements. We believe that our audit provides a reasonable basis for
our opinion.

/s/ KMJ Corbin & Company LLP

KMJ Corbin & Company LLP

We served as the Company’s auditor from 2020 to 2024.

Glendora, California

April 15, 2024

 F-3 

Mosaic ImmunoEngineering, Inc.

Consolidated Balance Sheets

    December 31, 2024  
    December 31, 2023 

    ASSETS 

    Current assets: 

    Cash and cash equivalents 
    $115,019  
    $156,178 
  
    Prepaid expenses and other current assets 
     26,592  
     23,355 
  
    Total current assets 
     141,611  
     179,533 
  
    Total assets 
    $141,611  
    $179,533 

    LIABILITIES AND STOCKHOLDERS’ DEFICIT 

    Current liabilities: 

    Accounts payable 
    $134,865  
    $118,478 
  
    Accrued compensation 
     3,767,652  
     3,184,911 
  
    Accrued consulting 
     787,903  
     787,903 
  
    Accrued expenses and other 
     646,850  
     641,763 
  
    Loan payable 
     200,000  
     – 
  
    Total current liabilities 
     5,537,270  
     4,733,055 

    Convertible notes, net 
     1,392,515  
     1,317,536 

    Total liabilities 
     6,929,785  
     6,050,591 

    Commitments and contingencies 
     –  

    Stockholders’ deficit: 

    Preferred stock, $0.00001 par value; 5,000,000 shares authorized: 
     –  

    Series A Convertible Voting Preferred Stock; 630,000 shares designated; no shares issued